Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized evaluator-blinded active-controlled study of CG2001 in Chinese adult men with androgenetic alopecia
CTR20263044Phase 3Active
- Sponsor
- Chenguang Pharmaceutical
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of CG2001 in androgenetic alopecia (AGA), sponsored by Chenguang Pharmaceutical. Started Aug 2026; status: active.
02
Drugs
CG2001
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on CTR20263044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263044.